Animal ID:
N/A
|
Host:
Rabbit
|
Reactivity:
Human
|
Storage:
Maintain refrigerated at 2-8oC for up to 6 months. For long term storage store ar -20oC. Avoid repeated freeze-thaw cycles.
|
|
Immunogen:
KLH conjugated synthethic peptide comprised of internal domain of the human Beta-site APP-cleaving Enzyme 1.
|
Accession number:
NM_012104
|
Description:
Bace 1 is responsible for the proteolytic processing of the amyloid precursor protein (APP). Cleaves at the N-terminus of the A-beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP, and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.
|
Alternative Name(s):
APP beta-secretase; asp2; aspartylprotease 2; Beta scretase 1; Memapsin 2
|
References:
- Sun X, He G, Qing H, Zhou W, Dobie F, Cai F, Staufenbiel M, Huang LE, and Song W: Hypoxia facilitates Alzheimer¿s disease pathogenesis by up-regulating BACE1 gene expression. Proc Natl Acad Sci U S A Dec 5, 103 (49): 18727-32 (2006).
- Durham TB, and Shepherd TA: Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Devel Nov. 9(6): 776-91 (2006) Review.
- McGaughey GB, Colussi D, Graham SL, Lai MT, Munshi SK, Nantermet PG, Pietrak B, Rajapakse HA, Selnick HG, Stauffer SR, and Holloway MK: beta-Secretase (BACE-1) inhibitors: Accounting for 10s loop flexibility using rigid active sites. Bioorg Med Chem Lett Nov. 6: (2006).
- Hu B, Xiong B, Qiu BY, Li X, Yu HP, Xiao K, Wang X, Li J, and Shen JK: Construction of a small peptide library related to inhibitor OM99-2 and its structure-activity relationship to beta-secretase. Acta Pharmacol Sin Dec. 27: 1586-93 (2006).
|
For Research Use Only. Not for Diagnostic or Therapeutic Use.
Purchase does not include or carry any right to resell or transfer this product either as a stand-alone product or as a component of another product. Any use of this product other than the permitted use without the express written authorization of Orbigen, Inc. is strictly prohibited
|
|
